Dr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman CULVER CITY, Calif. --(BUSINESS WIRE)--Aug. 10, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr.
Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA ®, driven by continued adoption among U.S.
The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum of BCG-unresponsive disease: carcinoma in situ (CIS) with or without papillary
Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 1, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster